Introduction to the Design and Evaluation of Group Sequential Clinical Trials Session 2 - Fixed Sample Trial Design & Motivating Examples

Presented July 26, 2017

Daniel L. Gillen Department of Statistics University of California, Irvine

John M. Kittelson Department of Biostatistics & Informatics University of Colorado Denver

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Introduction

Phases of the clinical trial process

- Phase I
 - Exploratory trials concerned with toxicology and pharmacology
 - Dosing trials
 - Typically between 20-80 healthy volunteers

Phase II

- Pilot studies to assess safety and efficacy
- Typically 100-300 diseased patients

Phase III

- Confirmatory trials
- Often over 1000 diseased patients

Phase IIIb/IV

- Post-marketing trials
- Observational monitoring of adverse events or new indications

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Fundamental Clinical Trial Design

Where are we going?

- Group sequential methods build on the foundations of fixed sample clinical trial design
- As such, it is useful to review some of the key elements of fixed sample trial design
- This will lead to the specification of a fixed sample study
- From that foundation we can then build in group sequential procedures

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Defining treatment(s)

- Treatment must be completely defined at the time of randomization
 - Dose(s)
 - Administration(s)
 - Frequency and duration
 - Ancillary treatments and treatment reduction protocol

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Defining the target population

- Inclusion/exclusion criteria to identify a population for whom
 - A new treatment is needed
 - Experimental treatment is likely to work
 - Expected to work equally well in all subgroups
 - All patients likely to eventually use the new treatment are represented (safety)
 - Clinical experimentation with the new treatment is not unethical

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks

Comparison groups Choice of summary

measure

Software

RCTdesign

Motivating Examples

Goals/discrimination of hypotheses

- A particular range of values that is of scientific interest for decisions is termed a "statistical hypothesis"
 - Example: Suppose θ is a scientifically appropriate summary measure of the distribution
 - ► Values of θ < 1.0 indicate a beneficial treatment (e.g., a ratio)
 - ► Values of θ > 1.0 indicate a harmful treatment (e.g., a ratio)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design Defining hypotheses Goals of statistical design

Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Goals/discrimination of hypotheses

 Definitions of statistical hypotheses corresponding to scientific importance

-Tendency to be larger: $\theta > 1.0$

-No tendency to be smaller: $\theta > 0.9$

-Approximate equivalence:

-No tendency to be larger:

-Tendency to be smaller:

 $0.8 < \theta < 1.2$

 $\theta < 1.2$

 $\theta < 1.0$

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Goals/discrimination of hypotheses

- We describe statistical analyses that discriminate between several of these hypotheses
 - One sided hypothesis tests
 - Two sided hypothesis tests
 - Two sided equivalence tests (e.g., bioequivalence)
 - One-sided equivalence (noniferiority) tests

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Goals/discrimination of hypotheses

- Classically, hypotheses are considered as
 - Null hypothesis
 - Status quo
 - Decision in absence of evidence to the contrary
 - Alternative hypothesis
 - What is to be proven
 - Decision if evidence suggests null hypothesis is false

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Goals/discrimination of hypotheses

- One sided hypothesis tests discriminate between two hypotheses
 - null hypothesis
 - alternative hypothesis (greater or lesser)
- Two sided hypothesis tests discriminate between three hypotheses
 - greater alternative
 - null hypothesis
 - lesser alternative

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Definitions of statistical hypotheses corresponding to scientific importance

- 1. One sided hypothesis tests:
 - Lesser alternative

Superiority: $\theta < 1.0 \text{ (reject } \theta > 1.0 \text{)}$

Nonsuperiority: $\theta > 0.6$ (reject $\theta < 0.6$)

• <u>Greater alternative</u>

Inferiority: $\theta > 1.0$ (reject $\theta < 1.0$)Noninferiority: $\theta < 1.8$ (reject $\theta > 1.8$)

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design Defining hypotheses

Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Definitions of statistical hypotheses corresponding to scientific importance

2. Two sided hypothesis tests:

Superiority: $\theta < 1.0 \text{ (reject } \theta > 1.0 \text{)}$

Equivalence: $0.6 < \theta < 1.8$ (reject $\theta < 0.6$; reject $\theta > 1.8$)

Inferiority: $\theta > 1.0$ (reject $\theta < 1.0$)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Definitions of statistical hypotheses corresponding to scientific importance

3. One-sided equivalence tests (noninferiority):

Noninferiority: $\theta < 1.2$ (reject $\theta > 1.2$)

Nonsuperiority: $\theta > 0.8$ (reject $\theta < 0.8$)

4. Two sided equivalence tests (bioequivalence):

Superiority: $\theta < 1.0$ (reject $\theta > 1.0$)Equivalence: $0.8 < \theta < 1.2$ (reject $\theta < 0.8$; reject $\theta > 1.2$)Inferiority: $\theta > 1.0$ (reject $\theta < 1.0$)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Goals/discrimination of hypotheses

Choices of hypotheses

- One-sided hypothesis test (superiority)
- Two-sided hypothesis test (superiority/inferiority)
- Two-sided equivalence test (eg. bioequivalence)
- One-sided equivalence (non-inferiority) test

How to choose?

- Base decision on what conditions will change current practice by:
 - Adopting a new treatment
 - Discarding an existing treatment

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups Choice of summary

Software

measure

RCTdesign

Motivating Examples

Conditions under which current practice will be changed

- 1. Adoption of a new treatment
 - Superiority
 - Better than using no treatment (efficacious)
 - Better than existing treatment
 - Equivalence or non-inferiority
 - Equal to some existing efficacious treatment
 - Not markedly worse than some existing efficacious treatment
- 2. Discarding an existing treatment
 - Inferiority
 - Worse than using no treatment (harmful)
 - Markedly worse than another treatment

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Ethical issues when specifying hypotheses

- Clinical versus biological (surrogate) endpoints
 - Typically, subjects participating in a trial are hoping that they will benefit in some way from the trial
 - Clinical endpoints are therefore of more interest than purely biological endpoints
 - For late stage trials, how well does the proposed surrogate correlate with the targeted clinical endpoint?

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical issues when specifying hypotheses

- Common pitfalls of experimentation are
 - Data driven hypotheses
 - Multiple comparisons
 - Poor selection of subjects
 - Over-fitting of data

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical issues when specifying hypotheses

"When you go looking for something specific, your chances of finding it are very bad, because of all the things in the world, you're only looking for one of them.

"When you go looking for anything at all, your chances of finding it are very good, because of all the things in the world, you're sure to find some of them."

- Darryl Zero in "The Zero Effect"

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical issues when specifying hypotheses

In Statistics-Speak "When you go looking for something specific, your chances of finding [a spurious association by chance] are very bad, because of all the things in the world, you're only looking for one of them.

"When you go looking for anything at all, your chances of finding [a spurious association by chance] are very good, because of all the things in the world, you're sure to find some of them."

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Goals of statistical design

- Interested in identifying beneficial treatments in such a way as to maintain
 - Scientific credibility
 - Ethical experiments
 - Efficient experiments
 - Minimize time
 - Minimize cost
- Basic goal: Attain a high positive predictive value with minimal cost

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks Comparison groups Choice of summary

Software

measure

RCTdesign

Motivating Examples

Predictive value of statistically significant result depends on

- 1. Probability of beneficial drug
 - Fixed when treatment is chosen
- 2. Specificity
 - Fixed by level of significance (alpha level)
- 3. Sensitivity
 - Statistical power made as high as possible by design

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Power is increased by

- 1. Minimizing bias
 - Remove confounding and account for effect modification
- 2. Decreasing variability of measurements
 - Homogeneity of population, appropriate endpoints, appropriate sampling strategy
- 3. Increasing sample size

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks Comparison groups Choice of summary

measure

Software

RCTdesign

Motivating Examples

Statistical tasks

- 1. Definition of the probability model
 - Comparison group
 - Refinement of statistical hypothesis
 - Method of analysis
- 2. Definition of statistical hypotheses
- 3. Definition of statistical criteria for evidence

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical tasks

- 4. Determination of sample size
- 5. Evaluation of operating characteristics
- 6. Planning for interim monitoring
- 7. Plans for analysis and reporting results

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Possible comparison groups

- 1. No comparison group
 - Single arm clinical trial (cohort design)
 - Appropriate when absolute criterion for treatment effect exists
- 2. Historical controls
 - Single arm clinical trial
 - Compare results to criteria defined from historical trial or sample from historical trial

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Possible comparison groups

- 3. Internal controls
 - Subject serves as his/her own control (cross-over design)
 - Different treatments at different times (washout period?)
 - Different treatment for different body parts (eg. eyes)
- 4. Concurrent control group
 - Two or more arms
 - Active treatments or more than one level of same treatment

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical hypotheses: Choice of summary measure

- Wish to determine the tendency for a new treatment to have a beneficial effect on a clinical outcome
- Consider the distribution of outcomes for individuals receiving intervention
 - Usually choose a summary measure of the distribution (eg. mean, median, proportion cured, etc)
 - Hypotheses then refined and expressed as values of the summary measure

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical hypotheses: Choice of summary measure

- Typically have many choices for the summary measure to compare across treatment groups
- Consider the distribution of outcomes for individuals receiving intervention
 - Example: Treatment of high blood pressure with a primary outcome of systolic blood pressure at end of treatment
 - Possible analyses might compare:
 - Average, median, percent above 160 mmHg, or mean or median time until blood pressure below 140 mm Hg

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical hypotheses: Choice of summary measure

- Choice of summary measure GREATLY affects the scientific relevance of the trial
- Summary measure should be chosen based on (in order of importance)
 - Most clinically relevant summary measure
 - Summary measure most likely to be affected by the intervention
 - Summary measure affording the greatest statistical precision

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical hypotheses: Choice of summary measure

- In addition to choosing the summary measure within groups, also need to choose how to contrast measures across groups
- Again many choices are available with different implications
 - Ex: Difference in means or proportions
 - Ex: Ratio of odds, medians, or risks (probabilities)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Software for evaluation/implementation of designs : RCTdesign

- Named seqDesign object (class)
 - Formatted output from RCTdesign
 - Predefined plotting functions and class routines

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Software for evaluation/implementation of designs : RCTdesign

- Sample size requirements
 - Printed with boundaries
 - X-axis with plots of boundaries
 - Plots of average sample size, quantiles of sample size distribution
- Stopping probabilities
 - Printed with operating characteristics
 - Plots with color coded decisions

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups Choice of summary

measure

Software

RCTdesign

Motivating Examples

Software for evaluation/implementation of designs : RCTdesign

- Power curve
 - Hypotheses, size, power printed with boundaries
 - Tabled power with summaries
 - Plots of power curve
 - Plots versus reference power curve

Decision boundary

- Printed on specified boundary scale
- Plots

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Software for evaluation/implementation of designs : RCTdesign

- Frequentist inference on the boundary
 - Printed with summary
 - Plots
- Bayesian inference on the boundary
 - Posterior probabilities implemented as a boundary scale
 - Median (mode) of posterior distribution
 - Credible intervals
- Futility measures
 - Implemented as boundary scale
 - Conditional and predictive approaches

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses
- Goals of statistical design
- Statistical tasks
- Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Case Study : Sepsis Trial

Background

- Critically ill patients often get overwhelming bacterial infection (sepsis), after which mortality is high
- Gram negative sepsis is often characterized by production of endotoxin, which is thought to be the cause of much of the ill effects of gram negative sepsis
- Hypothesis: Administering antibody to endotoxin may decrease morbidity and mortality
- Two previous randomized clinical trials showed a slight benefit
- There were no safety concerns at the inception of the trial

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Hodgkin's Trial (Survival Endpoint)

Definition of Treatment

- Single administration of antibody to endotoxin within 24 hours of diagnosis of sepsis
- Reductions in dose not applicable
- Ancillary treatments unrestricted

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses
- Goals of statistical design
- Statistical tasks
- Comparison groups
- Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Hodgkin's Trial (Survival Endpoint)
Defining the target population

- Patients in ICU with newly diagnosed sepsis
- Infected with gram negative organisms
 - culture proven
 - gram stain

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Defining the Comparison Group

- Need to ensure scientific credibility for regulatory approval
- Crossover designs impossible
- Ultimate decision:
 - Single comparison group treated with placebo
 - Not interested in studying dose response
 - No similar current therapy (still ethical to use placebo)
 - Randomized
 - Allow for causal inference
 - No blocking

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses
- Goals of statistical design
- Statistical tasks
- Comparison groups
- Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Defining the Outcomes of Interest

Goals:

- Primary: Increase survival
 - Long term (always best)
 - Short term (many other processes may intervene)
- Secondary: Decrease morbidity

Refinement of the primary endpoint

- Possible primary endpoints
 - Time to death
 - Mortality rate at a fixed point in time
 - Time alive out of ICU during fixed period of time

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Refinement of the primary endpoint

Sponsor's initial choice for primary endpoint: Mortality rate at a fixed point in time (binary data)

- Sponsor proposed 14 day mortality
- FDA countered with a suggestion of 28 day mortality

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Method of analysis

- Test for differences in binomial proportions
 - Ease of interpretation
 - 28 day mortality not a rare event
 - 1:1 correspondence with tests of odds ratio (for known baseline event rates)
- No adjustment for covariates
- Statistical information dictated by mean variance relationship of Bernoulli random variables:
 - Let Y_{ki} denote binary response (mortality at 28 days) for *i*-th subject in group k, k = 0, 1
 - $Y_{ki} \sim \mathcal{B}(1, \theta_k)$
 - $E[Y_{ki}] = \theta_k$ and $Var[Y_{ki}] = \theta_k(1 \theta_k)$

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Definition of statistical hypotheses

Null hypothesis

- No difference in mortality between groups
- Estimated baseline rate
 - 28 day mortality: 30%
 - (needed in this case to estimate variability)

Alternative hypothesis

- One-sided test for decreased mortality
- Targeted 28 day mortality rate in antibody arm: 25%
 - 5% absolute difference in mortality

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Criteria for statistical evidence

- Type I error: Probability of falsely rejecting the null hypothesis Standards:
 - Two-sided hypothesis tests: 0.050
 - One-sided hypothesis test: 0.025
- <u>Power</u>: Probability of correctly rejecting the null hypothesis (1-type II error)
- Popular choice: 80% power

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Determination of sample size

- Sample size chosen to provide desired operating characteristics
 - Type I error : 0.025 when no difference in mortality
 - Power : 0.80 when 5% absolute difference in mortality
 - Statistical variability based on mortality rate of 30% in placebo arm

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Determination of sample size

- General sample size formula:
 - δ = standardized alternative
 - Δ = difference between null and alternative treatment effects
 - V = variability of a single sampling unit
 - n = number of sampling units

$$n=\frac{\delta^2 V}{\Delta^2}$$

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Determination of sample size

Parameter values in the present case:

• $\delta = (z_{1-\alpha} + z_{\beta})$ with $\alpha = 0.025$ and $\beta = 0.80$

•
$$\Delta = \theta_{1,H_1} - \theta_{0,H_1} = -0.05$$

•
$$V = \theta_{1,H_1}(1 - \theta_{1,H_1}) + \theta_{0,H_1}(1 - \theta_{0,H_1}) =$$

.25 × .75 + .3 × .7 = .3975

n = sample size per arm

$$n = \frac{\delta^2 V}{\Delta^2} = \frac{(1.96 + .841)^2 \times .3975}{(-.05)^2} = 1247.97 \rightarrow 1248$$

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses
- Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Evaluation of operating characteristics

Critical values:

- Observed value which rejects the null hypothesis
- Point estimate of treatment effect
 - Will that effect be considered important?
 - (Clinical and marketing relevance)

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Evaluation of operating characteristics

Confidence interval at the critical value:

- Observed value which fails to reject the null hypothesis
- Set of hypothesized treatment effects which might reasonably generate data like that observed
 - Have we excluded all scientifically meaningful alternatives with a negative study?
 - If not, study is underpowered...

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Computation of design in RCTdesign

Primary function for defining any design in RCTdesign is seqDesign()

```
> binomFixed <- seqDesign( prob.model = "proportions", arms = 2,</pre>
         null.hypothesis = .3, alt.hypothesis = 0.25,
+
         ratio = c(1., 1.), nbr.analyses = 1,
+
                  test.type = "less", power = 0.80, alpha = 0.025)
+
> binomFixed
PROBABILITY MODEL and HYPOTHESES:
   Theta is difference in probabilities (Treatment - Comparison)
  One-sided hypothesis test of a lesser alternative:
           Null hypothesis : Theta >= 0.00
                                               (size = 0.025)
   Alternative hypothesis : Theta <= -0.05
                                               (power = 0.800)
   (Fixed sample test)
STOPPING BOUNDARIES: Sample Mean scale
                       Efficacy Futility
   Time 1 (N= 2495.9) -0.035 -0.035
```

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Inference on the boundary

Confidence intervals resulting from an observation at the critical value can be computed with seqInference()

<pre>> seqInference(</pre>	binomFixed)					
Ordering		*** a	Boundary	***	***	d Boundary ***
Time 1	Boundary		-0.035			-0.035
	MLE		-0.035			-0.035
	BAM		-0.035			-0.035
	RBadj		-0.035			-0.035
Mean	MUE		-0.035			-0.035
Mean	P-value		0.025			0.025
Mean	95% Conf Int		(-0.07,	0)		(-0.07, 0)
Time	MUE		-0.035			-0.035
Time	P-value		0.025			0.025
Time	95% Conf Int		(-0.07,	0)		(-0.07, 0)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Evaluation of operating characteristics

Operating characteristics with N=2496:

- Critical value : -0.035
- Corresponding p-value : 0.025
- 95% confidence interval : (-0.07, 0)
- Interpretation: Smallest magnitude of (observed) effect which would result in a significant result is a 3.5% decrease in mortality on the treatment arm with corresponding CI (-0.07, 0).

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks

Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)



- Problem: Sponsor was concerned that 2496 patients would be logistically infeasible and want to consider a design with 1700 patients
- We can use the update() function to update the original design

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary

measure Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Inference on the boundary

Confidence intervals on the boundary for the design with 1700 patients

> seqInference(binomFixed.1700)

	Ordering		***	а	Boundary	***	***	d Boundary	***
Time 1		Boundary			-0.042			-0.042	
		MLE			-0.042			-0.042	
		BAM			-0.042			-0.042	
		RBadj			-0.042			-0.042	
	Mean	MUE			-0.042			-0.042	
	Mean	P-value			0.025			0.025	
	Mean	95% Conf Int			(-0.085,	0)		(-0.085,	0)
	Time	MUE			-0.042			-0.042	
	Time	P-value			0.025			0.025	
	Time	95% Conf Int			(-0.085,	0)		(-0.085,	0)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Effect of changing sample size

Operating characteristics with N=1700:

- Critical value : -0.0424
- Corresponding p-value : 0.025
- 95% confidence interval : (-0.085, 0)
- Interpretation: Smallest magnitude of (observed) effect which would result in a significant result is a 4.24% decrease in mortality on the treatment arm with corresponding CI (-0.085, 0).

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical

Trial Design Defining hypotheses

Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Effect of changing sample size on power

Power curve can be plotted with the seqPlotPower() function



Difference in Proportions

SISCR

UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical

Effect of changing baseline event probability on power

- Because the statistical information is dictated by the baseline event probability for a binary outcome, should also assess potential impact on power if design assumptions are incorrect
- Again, this can easily be done with the update() function

Let's explore the impact on power under a baseline event probability of 0.2, 0.3, and 0.4.

```
> Fixed.3 <- binomFixed.1700
> Fixed.2 <- update( Fixed.3, null=.2, alt=.15 )
> Fixed.4 <- update( Fixed.3, null=.4, alt=.35 )</pre>
```

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Effect of changing baseline event probability on power

> seqPlotPower(Fixed.3, Fixed.4, Fixed.5)



SISCR UW - 2017

Introduction



Difference in Proportions

Background

- Hodgkin's lymphoma represents a class of neoplasms that start in lymphatic tissue
- Approximately 7,350 new cases of Hodgkin's are diagnosed in the US each year (nearly equally split between males and females)
- 5-year survival rate among stage IV (most severe) cases is approximately 60-70%

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Background (cont.)

- Common treatments include the use of chemotherapy, radiation therapy, immunotherapy, and possible bone marrow transplantation
- Treatment typically characterized by high rate of initial response followed by relapse
- Hypothesize that experimental monoclonal antibody in addition to standard of care will increase time to relapse among patients remission

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Definition of Treatment

- Administered via IV once a week for 4 weeks
- Patients randomized to receive standard of care plus active treatment or placebo (administered similarly)
- Treatment discontinued in the event of grade 3 or 4 AEs
- Primary analysis based upon intention-to-treat

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Defining the target population

- Histologically confirmed Hodgkin's lymphoma Grade 1-3
- Progressive disease requiring treatment after at least 1 prior chemotherapy
- Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary

measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Defining the Comparison Group

- Scientific credibility for regulatory approval
- Concurrent comparison group
 - inclusion / exclusion criteria may alter baseline rates from historical experience
 - crossover designs impossible
- Final Decision
 - Single comparison group treated with placebo
 - not interested in studying dose response
 - no similar current therapy
 - avoid bias with assessment of softer endpoints
 - Randomize
 - allow causal inference

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses Goals of statistical design Statistical tasks Comparison groups
- Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Defining the Outcomes of Interest

Goals:

- Primary: Increase relapse-free survival
 - Long term (always best)
 - Short term (many other processes may intervene)
- Secondary: Decrease morbidity

Refinement of the primary endpoint

- Definition of event
 - First occurrence of death or relapse (relapse defined as presence of measurable lesion at 3-month scheduled visits)
- Possible primary endpoints
 - Event rate at fixed point in time
 - Quantile of time to event distribution
 - Hazard of event

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Refinement of the primary endpoint

<u>Final Choice</u>: Comparison of hazards for event (censored continuous data)

- Duration of followup
 - Wish to compare relapse-free survival over 4 years
 - Patients accrued over 3 years in order to guarantee at least one year of followup for all patients
- Measures of treatment effect (comparison across groups)
 - Hazard ratio (Cox estimate; implicitly weighted over time)
 - No adjustment for covariates
 - Statistical information dictated by number of events (under proportional hazards, statistical information is approximately D/4)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Definition of statistical hypotheses

Null hypothesis

- Hazard ratio of 1 (no difference in hazards)
- Estimated baseline survival
 - Median progression-free survival approximately 9 months
 - (needed in this case to estimate variability)

Alternative hypothesis

- One-sided test for decreased hazard
 - Unethical to prove increased mortality relative to comparison group in placebo controlled study (always??)
- 33% decrease in hazard considered clinically meaningful
 - Corresponds to a difference in median survival of 4.4 months assuming exponential survival

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Criteria for statistical evidence

- Type I error: Probability of falsely rejecting the null hypothesis Standards:
 - Two-sided hypothesis tests: 0.050
 - One-sided hypothesis test: 0.025
- Power: Probability of correctly rejecting the null hypothesis (1-type II error) Popular choice:
 - ► 80% power

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary

Software

measure

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Determination of sample size

- Sample size chosen to provide desired operating characteristics
 - Type I error : 0.025 when no difference in mortality
 - Power : 0.80 when 33% reduction in hazard
- Expected number of events determined by assuming
 - Exponential survival in placebo group with median survival of 9 months
 - Uniform accrual of patients over 3 years
 - Negligible dropout

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Endpoint)

Motivating Examples

Sepsis Trial (Binary Endpoint) Hodgkin's Trial (Survival

Determination of sample size

- General sample size formula:
 - δ = standardized alternative
 - $\Delta = \log$ -hazard ratio
 - π_i = proporiton of patients in group *i*, *i* = 0, 1
 - D = number of sampling units (events)

$$D = \frac{\delta^2}{\pi_0 \pi_1 \Delta^2}$$

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses Goals of statistical design Statistical tasks Comparison groups
- Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Determination of sample size

Fixed sample test (no interim analyses):

•
$$\delta = (z_{1-\alpha} + z_{\beta})$$
 for size α and power β

For current study, we assume 1:1 randomization

•
$$\pi_0 = \pi_1 = 0.5$$

Number of events for planned trial:

$$D = \frac{(1.96 + 0.84)^2}{0.5^2 \times [\log(.67)]^2]} = 195.75$$

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Specification of fixed sample design using RCTdesign

Again, we can use the function seqDesign() for specifying the fixed sample design (prob.model="hazard")

PROBABILITY MODEL and HYPOTHESES: Theta is hazard ratio (Treatment : Comparison) One-sided hypothesis test of a lesser alternative: Null hypothesis : Theta >= 1.00 (size = 0.025) Alternative hypothesis : Theta <= 0.67 (power = 0.800) (Fixed sample test) STOPPING BOUNDARIES: Sample Mean scale a d

Time 1 (N= 195.75) 0.7557 0.7557

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint) Hodgkin's Trial (Survival Endpoint)

Determination of sample size (cont.)

- In general, it necessary to know the expected number of patients required to obtain the desired operating characteristics
- This is given by:

$$N = \frac{D}{\pi_0 \operatorname{Pr}_0[\operatorname{Event}] + \pi_1 \operatorname{Pr}_1[\operatorname{Event}]}$$

where *D* is the total number of required events and π_i is the proportion of patients allocated to group *i*

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

- Defining hypotheses
- Goals of statistical design
- Statistical tasks
- Comparison groups
- Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)
Determination of sample size (cont.)

- Under proportional hazards, Pr[Event] for each group depends upon
 - 1. The total followup (T_L) and accrual (T_A) time
 - 2. The underlying survival distribution
 - 3. The accrual distribution
 - 4. Drop-out

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Hodgkin's Trial (Survival Endpoint)

Ρ

Determination of sample size (cont.)

From the above, if we assume a uniform accrual pattern we have:

$$r[\text{Event}] = \int_{0}^{T_{A}} \Pr[\text{Event \& Entry at } t]dt$$

$$= \int_{0}^{T_{A}} \Pr[\text{Event} | \text{Entry at } t] \Pr[\text{Entry at } t]dt$$

$$= 1 - \int_{0}^{T_{A}} \Pr[\text{No Event} | \text{Entry at } t] \Pr[\text{Entry at } t]dt$$

$$= 1 - \frac{1}{T_{A}} \int_{0}^{T_{A}} \Pr[\text{No Event} | \text{Entry at } t]dt \quad (\text{unif acc})$$

$$= 1 - \frac{1}{T_{A}} \int_{0}^{T_{A}} S(T_{L} - t)dt$$

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Specification of fixed sample design using RCTdesign

- In RCTdesign this is automated assuming exponential survival using the function seqPHSubjects()
- For the Hodgkin's trial we assumed
 - Median survival in the control arm of 9 months
 - Uniform accrual over 3 years with one additional year of followup

```
> seqPHSubjects( survFixed, controlMedian=0.75,
                 accrualTime=3, followupTime=1 )
                              rate hazardRatio controlMedian nSubjects
 accrualTime followupTime
                          1 75.364
                                                          0.75
                                                                  226.09
                                           1.00
1
            3
            3
                          1 80.497
2
                                           0.67
                                                          0.75
                                                                  241.49
```

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Endpoint)

Motivating Examples

Determination of sample size (cont.)

- Interpretation:
 - In order to desire the required number of patients we would need to accrue:
 - N=76 patients per year for 3 years if the null hypothesis were true (Total of 228 patients)
 - N=81 patients per year for 3 years if the alternative hypothesis were true (Total of 243 patients)

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Evaluating the operating characteristics

- 1. Critical values
 - Observed value which rejects the null
 - Point estimate of treatment effect (clinical and marketing relevance?
- 2. Confidence interval at the critical value
 - Set of hypothesized treatment effects which might reasonably generate data like that observed
 - Have we excluded all scientifically meaningful alternatives with a negative study?
- 3. Statistical power across various alternatives
- 4. Bayesian posterior probabilities at the critical value (more later)
- Sensitivity to design assumptions (sample size and/or baseline survival)

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Endpoint)

Motivating Examples

Frequentist inference at the boundaries using RCTdesign

- In RCTdesign frequentist inference can be obtained with the seqInference() function
- Only required argument is the design to be used

<pre>> seqInference(</pre>	survFixed)						
Ordering		*** a	Boundary	***	***	d Boundary *	* * *
Time 1	Boundary		0.756			0.756	
	MLE		0.756			0.756	
	BAM		0.756			0.756	
	RBadj		0.756			0.756	
Mean	MUE		0.756			0.756	
Mean	P-value		0.025			0.025	
Mean	95% Conf Int		(0.571,	1)		(0.571,	1)
Time	MUE		0.756			0.756	
Time	P-value		0.025			0.025	
Time	95% Conf Int		(0.571,	1)		(0.571,	1)

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Statistical power using RCTdesign

Power can be computed using seqOC() or plotted using seqPlotPower()

```
> seqOC(survFixed, theta=seq(.4,1,by=.05))
Operating characteristics
          ASN Power.lower
 Theta
  0.40 195.75
                    1.0000
  0.45 195.75
                    0.9999
  0.50 195.75
                    0.9981
  0.55 195.75
                    0.9869
  0.60 195.75
                    0.9467
  0.65 195.75
                    0.8540
  0.70 195.75
                    0.7037
  0.75 195.75
                    0.5210
  0.80 195.75
                    0.3450
  0.85 195.75
                    0.2052
  0.90 195.75
                    0.1107
  0.95 195.75
                    0.0547
  1.00 195.75
                    0.0250
```

Fixed design (one analysis time)

> seqPlotPower(survFixed, dsnLbls=c("survFixed"))

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Hodgkin's Trial (Survival Endpoint)

Statistical power using RCTdesign

Power can be computed using seqOC() or plotted using seqPlotPower()



SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design

Statistical tasks

Comparison groups

Choice of summary measure

Software

RCTdesign

Motivating Examples

Re-designing the study

- Sponsor felt that attaining 75-80 patients per year would be unrealistic
- Wished to consider design operating characteristics assuming approximately uniform accrual of 50 patients per year while maintaining the same accrual time and follow up
- Problem: Need to determine the expected number of events if 50 subjects were accrued per year
- Solution: Solve backwards using the nEvents argument in seqPHSubjects(), substituting various numbers of events

SISCR UW - 2017

Introduction

Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary measure

Software

RCTdesign

Motivating Examples

Sepsis Trial (Binary Endpoint)

Hodgkin's Trial (Survival Endpoint)

Re-designing the study

After a (manual) iterative search, we find that if roughly 50 patients are accrued yearly (under the alternative), 121 events would be expected

	accrualTime	followupTime	rate	hazardRatio	controlMedian	nSubjects
1	3	1	46.584	1.00	0.75	139.75
2	3	1	49.757	0.67	0.75	149.27

SISCR UW - 2017

Introduction Scientific Investigation

Fundamental Clinical Trial Design

Defining hypotheses Goals of statistical design Statistical tasks Comparison groups Choice of summary

```
Software
```

measure

```
RCTdesign
```

Motivating Examples